US2024016836A1PendingUtilityA1

Treatment for gingivitis

Assignee: UNIV MELBOURNEPriority: Mar 14, 2017Filed: Jun 15, 2023Published: Jan 18, 2024
Est. expiryMar 14, 2037(~10.6 yrs left)· nominal 20-yr term from priority
A61K 2800/92A61K 2800/52A61K 6/838A61K 6/20A61K 9/0058A61Q 17/005A61K 8/64A61K 33/42A61K 8/24A61K 38/1709A61P 1/02A61P 31/04A61Q 11/00A61K 2800/58
74
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to compositions and their use for oral care. In particular, the compositions and methods are for maintaining oral health and/or treating various oral conditions such as gingivitis. The present invention relates to methods and uses of stabilized amorphous calcium phosphate (ACP) and/or stabilized amorphous calcium fluoride phosphate (ACFP) in the preparation of a medicament for reducing pathogenic oral bacteria at an oral site in an individual; increasing commensal oral bacteria at an oral site in an individual; decreasing the proportion of pathogenic oral bacteria at an oral site in an individual; inhibiting oral dysbiosis; reducing gingival inflammation in an individual in need thereof; treating gingivitis in an individual in need thereof; and treating chronic gingivitis in an individual in need thereof.

Claims

exact text as granted — not AI-modified
1 - 42 . (canceled) 
     
     
         43 . A method of inhibiting oral dysbiosis in an individual, comprising administering stabilized amorphous calcium phosphate (ACP) and/or stabilized amorphous calcium fluoride phosphate (ACFP) to the oral cavity of the individual, thereby inhibiting oral dysbiosis. 
     
     
         44 . A method of treating oral dysbiosis in an individual, comprising administering stabilized amorphous calcium phosphate (ACP) and/or stabilized amorphous calcium fluoride phosphate (ACFP) to the oral cavity of the individual, thereby treating oral dysbiosis. 
     
     
         45 . The method according to  claim 44 , wherein the oral dysbiosis is associated with an increase in pathogenic oral bacteria that are one or more of acidogenic, aciduric, and inflammogenic. 
     
     
         46 . The method according to  claim 45 , wherein the pathogenic oral bacteria are inflammogenic. 
     
     
         47 . The method according to  claim 45 , wherein the pathogenic oral bacteria comprise any one or more selected from  Streptococcus mutans, Actinomyces naeslundii, Veillonella parvula, Lactobacillus casei, Porphyromonas gingivalis, Tannerella forsythia Treponema denticola, Leptotrichia wadei, Leptotrichia shahii, Leptotrichia buccalis , and  Lautropia mirabilis.    
     
     
         48 . The method according to  claim 44 , wherein the oral dysbiosis is associated with a decrease in commensal oral bacteria of any one or more species that express one or both of arginine deiminase and nitrate reductase. 
     
     
         49 . The method according to  claim 48 , wherein the commensal oral bacteria comprise any one or more selected from  Corynebacterium durum, Rothia dentocariosa, Streptococcus mitis, Streptococcus sanguinis , and  Fusobacterium nucleatum.    
     
     
         50 . A method for increasing commensal oral bacteria at an oral site in an individual, the method comprising administering stabilized amorphous calcium phosphate (ACP) and/or stabilized amorphous calcium fluoride phosphate (ACFP) to the oral cavity of the individual, thereby increasing commensal oral bacteria at an oral site. 
     
     
         51 . The method according to  claim 50 , wherein the commensal oral bacteria comprise bacteria of any one or more species that express one or both of arginine deiminase and nitrate reductase. 
     
     
         52 . The method according to  claim 51 , wherein the commensal oral bacteria comprise any one or more selected from  Corynebacterium durum, Rothia dentocariosa, Streptococcus mitis, Streptococcus sanguinis , and  Fusobacterium nucleatum.    
     
     
         53 . A method of treating gingivitis in an individual in need thereof, the method comprising administering stabilized amorphous calcium phosphate (ACP) and/or stabilized amorphous calcium fluoride phosphate (ACFP) to the oral cavity of the individual, thereby treating gingivitis. 
     
     
         54 . The method according to  claim 53 , wherein the individual has a Modified Gingival Index score of 1. 
     
     
         55 . The method according to  claim 53 , wherein the individual has a Modified Gingival Index score of 2. 
     
     
         56 . The method according to  claim 53 , wherein the individual has a Modified Gingival Index score of 3. 
     
     
         57 . The method according to  claim 53 , wherein the individual is has a Modified Gingival Index score of 4. 
     
     
         58 . The method according to  claim 53 , wherein the method further comprises an initial step of identifying an individual having gingivitis. 
     
     
         59 . The method according to  claim 53 , wherein the method further comprises performing a dental procedure prior to administering stabilized amorphous calcium phosphate (ACP) and/or stabilized amorphous calcium fluoride phosphate (ACFP) to the oral cavity of the individual. 
     
     
         60 . The method according to  claim 59 , wherein the dental procedure is selected from debridement, scaling, root planning and any other procedure to remove subgingival or supragingival bacteria. 
     
     
         61 . The method according to  claim 53 , wherein the stabilized amorphous calcium phosphate (ACP) and/or stabilized amorphous calcium fluoride phosphate (ACFP) is phosphopeptide-stabilized. 
     
     
         62 . The method according to  claim 61 , wherein the phosphopeptide is a casein phosphopeptide. 
     
     
         63 . The method according to  claim 53 , wherein the stabilized ACP and/or stabilized ACFP is administered to the individual for 5 to 60 minutes, 10 to 45 minutes, 10 to 30 minutes or 20 minutes. 
     
     
         64 . The method according to  claim 53 , wherein the stabilized ACP and/or stabilized ACFP is administered 4, 5 or 6 times per day, or per 24 hour period. 
     
     
         65 . The method according to  claim 53 , wherein the stabilized ACP and/or stabilized ACFP is administered for a 1 to 2 week period. 
     
     
         66 . The method according to  claim 53 , wherein the stabilized ACP and/or stabilized ACFP is formulated in any one of the following: toothpastes, toothpowders and liquid dentifrices, mouthwashes, mouthrinses, mouth sprays, varnish, dental cement, troches, chewing gums, dental pastes, gingival massage creams, gargle tablets, dairy products, and other foodstuffs.

Join the waitlist — get patent alerts

Track US2024016836A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.